A Global Leader in Antibiotics
As the global leader in generic antibiotics, Sandoz plays a critical role in ensuring the sustainability of global healthcare systems: antibiotics are the cornerstone of healthcare today. In addition to treating a wide range of infectious diseases, antibiotics are critical to guarantee patient safety during in-hospital medical procedures such as transplants.
Sandoz has a rich tradition of providing high-quality antibiotics. We led the way in supplying desperately needed antibiotics to the post-war Austrian population and produced the first ever oral penicillin in 1951. Our commitment to the successful outcomes of patients using our products has elevated us to become one of the world’s biggest producers of antibiotics.
We are proud to offer a comprehensive antibiotic portfolio consisting of Penicillins, Cephalosporins and Macrolides – products that form the backbone of global healthcare. We are committed to shaping the optimal environment that sustains the effectiveness of all antibiotics.
Overview of Our Antibiotic Business
An investment in the long-term success of this important medicine:
- Sandoz is the largest generic antibiotic manufacturer in the world, with 300 million packs of antibiotics produced annually
- Sandoz owns last remaining production facility in Western Europe, located in Kundl, Austria
- Sandoz is the 3rd largest maker of antibiotics globally and we produce the active pharmaceutical ingredients (API) for other leading companies
- The Sandoz portfolio of antibiotics covers over 50% of the antibiotics available giving us the opportunity to serve a broad majority of today’s antibiotic needs
- Antibiotics is the largest and oldest business at Sandoz
Strong Commitment Advancing Antibiotic Treatment
Our leadership position gives us the opportunity to remind people not only about the importance of antibiotics, but also about using them responsibly, including the best stewardship practices. Growing antimicrobial resistance (AMR) is one of the major threats to global health today. Indeed, the WHO estimates that it could lead to an additional 10 million annual deaths by 2050 if uncontrolled – more than the total number of deaths from all infectious diseases worldwide in 2012 (9.5 million). Sandoz is committed to work with other stakeholders to tackle the root causes of AMR, with a particular focus on increasing understanding of AMR and rational use of antibiotics, promoting the appropriate use of antibiotics (implementation of therapeutic guidelines, for instance on first and second line use, as well as driving prescription-only use), and ensuring stable manufacturing and secure supply.
In addition to producing generic antibiotics, as part of the Novartis Group, we are committed to Novel Antibiotics research to understand mechanisms of occurrence of AMR to identify new targets against the most important nosocomial and opportunistic infections. Novartis also supports the “Innovative Medicines Initiative” of the EU which invests 344 million EUR into antimicrobial resistance measures and activities.
We also support measures for the adoption of novel formulations and incremental Innovations. While novel antibiotics may take years to develop, manufacturers are able to develop new formulations much more quickly. These novel formulations – such as pediatric dosage forms – can help decrease non-adherence to therapy which is also an important cause of AMR.
Through our own Development efforts, Sandoz is actively working to ensure the broadest generic portfolio is always available, providing the opportunity for targeted treatments to match the infection. We plan to add to this portfolio over the next several years.